UK Primary Immunodeficiency Network logo
HomeStandards of CareDiagnoseMembersAccreditationMeetingRegistrationRegistryFind
 

Home

Aims and Organisation

Constitution

News Archive

Swine Flu

Minutes

Links

Contact

Search

 

About UKPIN

 

The UK Primary Immunodeficiency Network (UKPIN) is a multidisciplinary organisation of those caring for patients with primary immunodeficiencies. UKPIN aims to share methods of best practice, and to accredit immunology centres which practice in this way. Please explore these pages to see the wealth of reports, guidelines and other information available here.

Latest News

06.12.11: The revised minutes of the UKPIN Group Steering Committee of the 29 September 2011 have been posted here.

20.11.11: Fifteenth Biennial Meeting of the European Society for Immunodeficiencies (ESID)

ESID 2012 will gather over 3000 scientists and clinicians specializing in Primary Immunodeficiency Diseases. ESID 2012 offers an advanced scientific programme with a leading international faculty, new approaches to diagnosis and treatments, interactive discussions, opportunities for collaborative research, and networking events. For more details, click on the banner below.

Fifteenth Biennial Meeting of the European Society for Immunodeficiencies

17.10.11: UKPIN Position Statement

The electronic copy of the UKPIN Position Statement on 'Immunoglobulin Product Choice for Patients with Primary Immunodeficiency' has been posted here.

17.10.11: Advances in Primary Immunodeficiency

A Winter School run by the UCL Centre for Immunodeficiency.

The UCL Centre for Immunodeficiency is running a three day residential course covering adaptive and innate primary immunodeficiency disease (PID), which will take place at Cumberland Lodge, the Great Park of Windsor, UK, from 12th – 14th March 2011. For more details, download the Word/PDF document below:

PDF

UCL Winterschool 2012 Advertisement

Word Doc

UCL Winterschool 2012 Program

 

 

 


UKPIN is sponsored by Baxter, Biotest, BPL, CSL Behring, Grifols, Octapharma, and Shire.